The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer

Van Cutsem Eric; Mayer Robert J.; Laurent Stephanie; Winkler Robert; Gravalos Cristina; Benavides Manuel; Longo-Munoz Federico; Portales Fabienne; Ciardiello Fortunato; Siena Salvatore; Yamaguchi Kensei; Muro Kei; Denda Tadamichi; Tsuji Yasushi; Makris Lukas; Loehrer Patrick; Lenz Heinz-Josef; Ohtsu Atsushi

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer

【24h】

The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer

机译：Trifluridine / Tipiracil（Tas-102）的III期递交试验的亚组与转移结直肠癌患者最佳支持性护理的安慰剂

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: In the phase III RECOURSE trial, trifluridine/tipiracil (TAS-102) extended overall survival (OS) and progression-free survival (PFS) with an acceptable toxicity profile in patients with metastatic colorectal cancer refractory or intolerant to standard therapies. The present analysis investigated the efficacy and safety of trifluridine/tipiracil in RECOURSE subgroups.

机译：背景：在III期追求试验中，Trifluridine / Tipiracil（Tas-102）将整体存活（OS）和无进展的存活（PFS）延长，具有可接受的毒性型患者在转移性结肠直肠癌难治性或不耐受标准疗法中。本分析研究了Trifluridine / Tipiracil在追求亚组中的疗效和安全性。

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2018年第2018期|共10页
作者
Van Cutsem Eric; Mayer Robert J.; Laurent Stephanie; Winkler Robert; Gravalos Cristina; Benavides Manuel; Longo-Munoz Federico; Portales Fabienne; Ciardiello Fortunato; Siena Salvatore; Yamaguchi Kensei; Muro Kei; Denda Tadamichi; Tsuji Yasushi; Makris Lukas; Loehrer Patrick; Lenz Heinz-Josef; Ohtsu Atsushi;
展开▼
作者单位

Univ Hosp Gasthuisberg Digest Oncol Herestr 49 B-3000 Leuven Belgium;

Dana Farber Canc Inst 450 Brookline Ave Boston MA 02215 USA;

Univ Hosp Ghent De Pintelaan 185 B-9000 Ghent Belgium;

Taiho Oncol Inc 101 Carnegie Ctr Princeton NJ 08540 USA;

Hosp Univ 12 Octubre Ave Cordoba S-N Madrid 28041 Spain;

Hosp Reg Univ Malaga Ave Carlos Haya S-N Malaga 29011 Spain;

Hosp Univ Ramon y Cajal Carretera Colmenar Viejo Km 9 100 Madrid 28034 Spain;

CRLC Val dAurelle 208 Ave Apothicaires F-34298 Montpellier France;

Seconda Univ Napoli Via Antonio Vivaldi 43 I-81100 Caserta Italy;

Univ Milan Via Festa Perdono 7 I-20122 Milan Italy;

Japanese Fdn Canc Res Canc Inst Hosp 3-8-31 Ariake Tokyo 1358550 Japan;

Aichi Canc Ctr Hosp Chikusa Ku 1-1 Kanokoden Nagoya Aichi 4648681 Japan;

Chiba Canc Ctr Chuo Ku 666-2 Nitona Cho Chiba 2608717 Japan;

Tonan Hosp Chuo Ku N1 W6 Sapporo Hokkaido 0600001 Japan;

Stathmi Inc 125 Brownsburg Rd New Hope PA 18938 USA;

Indiana Univ Melvin &

Bren Simon Canc Ctr 535 Barnhill Dr Indianapolis IN 46202 USA;

USC Norris Comprehens Canc Ctr 1441 Eastlake Ave Los Angeles CA 90089 USA;

Natl Canc Ctr Hosp East 6-5-1 Kashiwanoha Kashiwa Chiba 2778577 Japan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Fluoropyrimidine; Metastatic colorectal cancer; Randomised controlled trial; TAS-102; Tipiracil; Trifluridine;

机译：氟嘧啶;转移性结肠直肠癌;随机对照试验;TAS-102;TIPIRACIL;三氟乙醛;

相似文献

外文文献
中文文献
专利

1. CMAB009联合伊立替康或伊立替康单药二线治疗氟嘧啶和奥沙利铂治疗失败的KRAS野生型转移性结直肠癌患者的研究:一项前瞻性、开放、随机、Ⅲ期试验 [J] . 石远凯, 白丽, 张沂平, 癌症（英文版） . 2020,第007期
2. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer [J] . Van Cutsem Eric, Mayer Robert J., Laurent Stephanie, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2018,第期

机译：Trifluridine / Tipiracil（Tas-102）的III期递交试验的亚组与转移结直肠癌患者最佳支持性护理的安慰剂
3. EFFICACY AND SAFETY FROM RECOURSE: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAS-102 VERSUS PLACEBO WITH BEST SUPPORTIVE CARE IN PATIENTS WITH METASTATIC COLORECTAL CANCER REFRACTORY TO STANDARD THERAPIES. [J] . Ferencz Thomas, Hochster Howard, Atalla Gihan, Oncology nursing forum . 2016,第2期

机译：疗效和安全性：多中心，随机，双盲，第3阶段TAS-102与PLACEBO的最佳支持治疗在转移性大肠癌耐火性达到标准治疗的患者中进行。
4. EFFICACY AND SAFETY FROM RECOURSE: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAS-102 VERSUS PLACEBO WITH BEST SUPPORTIVE CARE IN PATIENTS WITH METASTATIC COLORECTAL CANCER REFRACTORY TO STANDARD THERAPIES. [J] . Ferencz Thomas, Hochster Howard, Atalla Gihan, Oncology nursing forum . 2016,第2期

机译：追索权疗效和安全性：多中心，随机，双盲，第3期与标准疗法难以解决的患者最佳的支持性护理。
5. Effects of laser immunotherapy on late-stage, metastatic breast cancer patients in a Phase Ⅱ clinical trial [C] . Gabriela L. Ferrel, Feifan Zhou, Xiaosong Li, Biophotonics and immune responses IX . 2014

机译：Ⅱ期临床试验中激光免疫疗法对晚期转移性乳腺癌患者的影响
6. Supportive Care for Patients with Breast Cancer by Using an Interactive App During Neoadjuvant Chemotherapy: A Randomized Controlled Trial [D] . Fjell, Maria. 2021

机译：通过在Neoadjuvant化疗期间使用互动性应用的乳腺癌患者的支持性护理：随机对照试验
7. Efficacy of trifluridine and tipiracil (TAS-102) versus placebo with supportive care in a randomized controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial [O] . F. Longo-Muñoz, G. Argiles, J. Tabernero, -1

机译：在西班牙转移性结直肠癌患者的随机对照试验中三氟吡啶和替吡西酯（TAS-102）与安慰剂联合支持治疗的疗效：RECOURSE 3期试验的亚组分析结果
8. Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial [O] . 2017

机译：在西班牙转移性结直肠癌患者的随机对照试验中，三氟吡啶和替吡西酯（TAS-102）与安慰剂联合支持治疗的疗效：RECOURSE 3期试验的亚组分析结果

The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer

摘要

著录项

相似文献

相关主题

期刊订阅